Reducing Perioperative Oxidative Stress to Prevent Postoperative Chronic Pain Following Total Knee Arthroplasty

PHASE4RecruitingINTERVENTIONAL
Enrollment

148

Participants

Timeline

Start Date

December 6, 2024

Primary Completion Date

September 30, 2028

Study Completion Date

March 31, 2029

Conditions
Osteoarthritis, KneeTotal Knee ArthroplastyChronic Postsurgical Pain
Interventions
DRUG

GlyNAC (combination of glycine and n-acetylcysteine)

GlyNAC 200 mg/kg/day (100mg glycine and 100mg N-acetyl-cysteine) will be administered orally in two divided doses each day for four weeks prior to TKA and six weeks postoperatively. The preparation will be a commercially available product of 1:1 ratio of glycine and N-acetyl-cysteine.

DRUG

Placebo

Placebo (alanine) 200 mg/kg/day will be administered orally in two divided doses each day for four weeks prior to TKA and six weeks postoperatively.

Trial Locations (1)

37212

RECRUITING

Vanderbilt University Medical Center, Nashville

All Listed Sponsors
collaborator

National Institute on Aging (NIA)

NIH

lead

Vanderbilt University Medical Center

OTHER

NCT06083480 - Reducing Perioperative Oxidative Stress to Prevent Postoperative Chronic Pain Following Total Knee Arthroplasty | Biotech Hunter | Biotech Hunter